Sandbox:Roukoz: Difference between revisions

Jump to navigation Jump to search
No edit summary
No edit summary
Line 5: Line 5:
{{familytree | | | | | | | | | | | | |!| | | | | | | | | }}
{{familytree | | | | | | | | | | | | |!| | | | | | | | | }}
{{familytree | | | | | | | | | | | | C01 | | | | | | |C01=Histopathologic examination}}
{{familytree | | | | | | | | | | | | C01 | | | | | | |C01=Histopathologic examination}}
{{familytree | | | | | | |,|-|-|-|-|-|+|-|-|-|-|-|.| | }}
{{familytree | | | | | |,|-|-|-|-|-|-|+|-|-|-|-|-|.| | }}
{{familytree | | | | | |D01| | | | | D02| | | D03 | |D01='''Squamous cell carcinoma'''|D02='''Neuroendocrine carcinoma'''|D03='''Adenocarcinoma and poorly differntiated carcinoma'''}}
{{familytree | | | | |D01| | | | | D02| | | D03 | |D01='''Squamous cell carcinoma'''|D02='''Neuroendocrine carcinoma'''|D03='''Adenocarcinoma and poorly differntiated carcinoma'''}}
{{familytree | | | | | |!| | | | | | |!| | | | | |!| | }}
{{familytree | | | | | |!| | | | | | |!| | | | | |!| | }}
{{familytree | | | | |E01| | | | | E02 | | | | E03 | | |E01=Additional tests specific to location of metastasis|E02=• Octreoscan<br> • Plasma chromogranin A|E03=Gender specific tests}}
{{familytree | | | | |E01| | | | | E02 | | | | E03 | | |E01=Additional tests specific to location of metastasis|E02=• Octreoscan<br> • Plasma chromogranin A|E03=Gender specific tests}}

Revision as of 19:40, 10 October 2018

 
 
 
 
 
 
 
 
 
 
 
Tumor of unknown primary origin
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
• Full medical history and physical exam
• Basic blood and bichemical analysis
• CT scan of chest, abdomen, and pelvis
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Histopathologic examination
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Squamous cell carcinoma
 
 
 
 
Neuroendocrine carcinoma
 
 
Adenocarcinoma and poorly differntiated carcinoma
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Additional tests specific to location of metastasis
 
 
 
 
• Octreoscan
• Plasma chromogranin A
 
 
 
Gender specific tests
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
boneIng
 
Supra
 
 
 
 
 
 
 
dasd
 
 
asd